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sustained	 virological	 response	 at	 12	weeks	 post-	completion	 of	 therapy	 (SVR12),	
but	are	costly.	We	aimed	to	assess	the	efficacy	of	generic	oral	DAAs	in	a	real-	life	
clinical	scenario.	Consecutive	patients	with	known	HCV	infection	who	were	treated	
with	 generic-	oral	 DAA	 regimens	 (May	 2015	 to	 January	 2017)	 were	 included.	
Demographic	 details,	 prior	 therapy	 and	 SVR12	were	 documented.	 Four	 hundred	
and	ninety	patients	(mean	age:	38.9	±	12.7	years)	were	treated	with	generic	DAAs	
in	 the	 study	 time	 period.	 Their	 clinical	 presentations	 included	 chronic	 hepatitis	
(CHC)	 in	339	 (69.2%)	of	cases,	compensated	cirrhosis	 in	120	 (24.48%)	cases	and	
decompensated	 cirrhosis	 in	 31	 (6.32%)	 cases.	 Genotype	 3	 was	 most	 common	
(n	=	372,	 75.9%)	 followed	 by	 genotype	 1	 (n	=	97,	 19.8%).	 Treatment	 naïve	 and	
treatment-	experienced	 (defined	as	having	previous	 treatment	with	peginterferon	
and	ribavirin)	were	432	(88.2%)	and	58	(11.8%),	respectively.	Generic	DAA	treat-
ment	 regimens	 included	 sofosbuvir	 in	 combination	 with	 ribavirin	 (n	=	175),	 da-
clatasvir	 alone	 (n	=	149),	 ribavirin	 and	 peginterferon	 (n	=	80),	 ledipasvir	 alone	
(n	=	43),	daclatasvir	and	ribavirin	(n	=	37),	and	ledipasvir	and	ribavirin	(n	=	6).	Overall	
SVR12	was	95.9%	(470/490)	for	all	treatment	regimens.	SVR12	for	treatment	naïve	
and	experienced	patients	was	97.0%	 (419/432)	 and	87.9%	 (51/58),	 respectively,	
P	=	.005.	High	SVR12	was	observed	with	various	 regimens,	 irrespective	of	geno-
type	and	underlying	liver	disease	status.	There	were	no	differences	in	SVR12	with	
12	 or	 24	weeks	 therapy.	 No	 major	 adverse	 event	 occurred	 requiring	 treatment	
stoppage.	Generic	oral	DAAs	are	associated	with	high	SVR	rates	 in	patients	with	
HCV	infection	in	a	real-	life	clinical	scenario.
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1  | INTRODUCTION
Hepatitis	 C	 virus	 (HCV)	 infection	 poses	 a	 significant	 public	 health	
concern	 with	 an	 estimated	 2%-	3%	 overall	 global	 prevalence,	 and	
0.9%-	1.9%	 prevalence	 in	 India.1	 The	 vast	 majority	 of	 patients	 (up	
to	 80%)	 who	 have	 HCV	 develop	 chronic	 hepatitis	 that	 can	 prog-
ress	to	chronic	liver	disease,	cirrhosis	and	hepatocellular	carcinoma.	
Novel	 direct-	acting	 antivirals	 (DAAs)	 are	 now	 the	 standard	of	 care	
for	the	management	of	HCV	infection.	Moreover,	recent	HCV	man-
agement	 guidelines	 recommend	 that	 all	 patients	 positive	 for	 HCV	
RNA	 be	 considered	 for	 therapy	 irrespective	 of	 the	 serum	 alanine	























different	 treatment	 regimens,	 hepatitis	C	genotypes	 and	 severity	of	
liver	disease.
2  | PATIENTS AND METHODS
2.1 | Inclusion and exclusion criteria
In	 this	 prospective	 study,	 all	 consecutive	 HCV-	positive	 patients	
evaluated	 in	 the	 Department	 of	 Gastroenterology	 at	 the	 All	 India	
























High	viral	 load	was	defined	as	≥600	000	IU/mL,	 and	 low	viral	
load	 was	 defined	 as	 <600	000	IU/mL.	 HCV	 RNA	 quantification	
was	 performed	 at	 baseline,	 end	 of	 therapy	 and	 12	weeks	 post-	
treatment	 (SVR12).	 SVR12	was	 achieved	 if	 HCV	 RNA	was	 nega-
tive/below	detectable	limit.	While	all	patients	had	HCV	RNA	levels	
checked	at	baseline,	end	of	treatment	and	SVR12,	several	patients	
had	HCV	viral	 loads	 checked	 at	 additional	 intervals.	 The	 diagno-
sis	of	cirrhosis	was	based	on	histologic	findings	on	liver	biopsy,	fi-
broscan	showing	a	 liver	stiffness	≥12.5	KPa	(Echosens,	France)	or	
a	 combination	 of	 conventional	 endoscopic	 (varices,	 gastric	 antral	
vascular	ectasia	or	portal	hypertensive	gastropathy	on	esophago-
gastroduodenoscopy)	 and	 imaging	 criteria	 (CT	 scan	or	ultrasound	
findings	 concerning	 for	 cirrhosis).	 Decompensated	 cirrhosis	 was	
defined	as	the	presence	of	jaundice,	ascites,	variceal	haemorrhage	
or	hepatic	encephalopathy.	The	model	 for	end-	stage	 liver	disease	
(MELD)	 score12	was	 calculated	 at	 baseline	 and	 after	12	weeks	of	












mained	 the	backbone	of	all	 combination	 therapies.	 Initially,	when	so-
fosbuvir	alone	was	available,	a	combination	of	sofosbuvir	with	ribavirin	





previously	 relapsed	or	did	not	 respond	 to	 interferon-	based	 regimens,	
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and	in	patients	with	cirrhosis;	the	duration	of	therapy	in	these	patients	
was	24	weeks	as	combination	therapy	with	sofosbuvir.	Patients	were	
followed	until	 the	end	of	 therapy	and	then	had	follow-	up	studies	 for	
a	 further	12	weeks.	Various	DAA	combination	drugs	were	purchased	
by	patients	with	prescriptions.	Many	patients	 (n	=	220)	were	not	able	
to	afford	 the	medications	and	 received	 the	generic	drugs	 (sofosbuvir	







as	 median	 (inter-	quartile	 range).	 Categorical	 data	 are	 presented	 as	
frequency	and	percentage.	Univariate	analysis	was	performed	to	as-
sess	the	factors	associated	with	SVR12	using	an	independent	t	test	or	








A	 total	 of	 683	 HCV-	positive	 patients	 were	 evaluated	 during	 the	
study	 period	 and	 recommended	 to	 initiate	 DAA	 therapy.	 Of	 these	
patients,	193	were	excluded	because	of	an	inability	to	afford	therapy	
or	 incomplete	 follow-	up	 after	 the	1st	 visit	 (n	=	65),	 ongoing	 therapy	
(n	=	90),	chronic	kidney	disease	(n	=	28),	co-	infection	with	HBV	(n	=	8)	
and	 HIV	 (n=2)	 (Figure	 1).	 Of	 the	 490	 patients	 included	 (mean	 age	
38.9	±	12.7	years),	 clinical	 presentations	 included	 chronic	 hepatitis	
(n	=	339,	69.2%),	compensated	cirrhosis	(n	=	120,	24.5%)	and	decom-
pensated	 cirrhosis	 (n	=	31,	 6.3%).	Genotype	3	was	most	 common	 in	
372	(75.9%)	patients	followed	by	genotype	1	in	97	(19.8%).	There	were	
432	 (88.2%)	 treatment	 naïve	 and	58	 (11.8%)	 treatment-	experienced	
(defined	 as	 previous	 treatment	with	 peginterferon	 and	 ribavirin)	 pa-
tients.	Pretreatment	high	viral	 load	was	observed	in	242	(49.4%)	pa-
tients.	The	clinical	and	demographic	details	are	shown	in	Table	1.
3.2 | SVR according to genotype, underlying liver 
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The	details	 of	various	 combinations	 using	 sofosbuvir	 are	 shown	 in	
Figure	1.	The	SVR12	in	genotype	1	CHC	and	cirrhosis	were	92.4%	(61/66)	
and	85.7%	(18/21),	respectively.	Only	six	genotype	1	patients	received	




The	SVR12	 in	genotype	3	CHC	was	97.5%	 (177/120)	 in	 the	 sofos-










nonresponders	 to	 peginterferon	 and	 ribavirin)	 had	 a	 lower	 SVR12	
(87.9%)	as	compared	to	treatment-	naïve	patients	(97.0%),	odds	ratio	
(OR)	0.226,	95%	CI	(0.086-	0.593).	The	rates	of	SVR12	with	the	treat-
ment	 regimen	of	 sofosbuvir,	 ledipasvir	 and	 ribavirin	 in	 combination	












3.4 | Patients lost to follow- up and relapsers
Seven	 patients	 (including	 one	 breakthrough)	 were	 documented	 to	
have	 relapsed	on	 the	basis	of	positive	HCV	RNA	after	12	weeks	of	
therapy.	 Thirteen	 treatment-	naïve	 patients	 were	 lost	 to	 follow-	up	
and	were	treated	as	nonresponders	when	analysing	outcomes	(total	
n	=	20).	 There	 were	 no	 treatment-	experienced	 patients	 who	 were	
lost	 to	 follow-	up.	 All	 relapsers	 to	 sofosbuvir-	based	 therapy	 were	
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3.5 | Change in MELD score at 12 weeks post- 
therapy














tients	 who	 received	 generic	 DAA	 treatment	 for	 HCV	 genotype	
3	 infection,	 which	 is	 highly	 prevalent	 in	 India.	 A	 paradigm	 shift	
from	 interferon-	based	 therapies	 to	 interferon-	free	 regimens	 has	





achieved	 globally	 by	 treatment	 with	 DAAs;	 however,	 the	 major	













those	 reported	previously	 from	other	 studies	performed	 in	 the	 Indian	
subcontinent.16-18	 Prior	 multicenter	 studies	 evaluating	 the	 efficacy	 of	
branded	DAA	have	 reported	similar	high	SVR12	 rates.5-7,19	Our	 study	
supports	the	fact	that	generic	DAAs	are	associated	with	high	efficacy.
A	 recent	 review	on	efficacy	and	 safety	of	oral	DAA	 reported	an	











CHC (SVR12) Cirrhosis (SVR12)
Decompensated 
cirrhosis (SVR12) P value
Genotype	1 61/66	(92.4%) 18/21	(85.7%) 10/10	(100%) .377
Genotype	2 2/2	(100%) 1/1	(100%) -	
Genotype	3 248/257	(96.5%) 92/94	(97.9%) 20/21	(95.2%) .747
Genotype	4 8/8	(100%) 3/3	(100%) -	 -	
Genotype	5 2/2	(100%) -	 -	 -	
NOS 4/4	(100%) 1/1	(100%) -	 -	










217/227	(95.4%) 32/34	(94.1%) 2/3	(66.7%) 0.068
24	wks	therapy
	(n	=	226)
108/112	(95.9%) 83/86	(96.5%) 28/28	(100%) 0.600
Total	(n	=	490) 339 120 31
TABLE  3 SVR12	rates	according	to	the	
duration	of	therapy




type	3	patients	 treated	with	 sofosbuvir	and	daclatasvir	 combination	

























We	 did	 not	 find	 any	 significant	 difference	 in	 the	 MELD	 score	
after	 12	weeks	 of	 therapy	 as	 compared	with	 baseline.	This	may	 be	
because	 the	mean	MELD	 score	 at	 baseline	was	 low,	 and	 therefore,	
the	 fractional	 change	was	 not	 significant.	 Prospective	 studies	 need	
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generic	 drug	 combinations.	Generic	 drugs	have	 certain	 limitations,	 as	
compared	to	branded	drugs.	Branded	drugs	undergo	extensive	testing	
for	quality,	safety	and	efficacy.	There	is	no	post-	marketing	surveillance	
for	 generics.	We	 used	multiple	 generic	 brands;	 however,	we	 did	 not	
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